<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="disrupt">
            <roleset id="Disrupt.01" name="" wordnet="1, 2">
                <roles>
                    <role n="0" descr=" agent" />
                    <role n="1" descr=" entity disrupted &#x0A;" />
                    <role n="R" descr=" results/consequences&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>It is important to note that the findings disrupt that inhibition of inflammation has not interrupts protective physiological responses.</text>
                    <arg n="0">inhibition of inflammation</arg>
                    <arg n="1">protective physiological responses</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>It is important to stress that a homozygous mutation has the no that disrupt pulally.</text>
                    <arg n="0">a homozygous mutation</arg>
                    <arg n="1">pulally</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>It is important to stress that exposure to alcohol consumption is able to disrupt ocular domain plasticity.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>It is important to stress that the findings show that this deletion could disrupt the open reading frame.</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">the open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Quantitative electrophysiology of a single unit revealed that homozygous mutation has been able to disrupt squirrel preserving robust visual responses.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">squirrel</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (this deletion that disrupted open reading frame, the Arg243----His mutation, a site Hha I and the Asp250----Asn mutation, a site Taq I) and the hybridization of allele-specific oligonucleotides confirmed that the patients were indeed composit</text>
                    <arg n="0">this deletion</arg>
                    <arg n="1">open reading frame</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (exposure to alcohol consumption being able to disrupt plasticity of eye dominance, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">plasticity of eye dominance</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (his retired expression MEKK1 or MEKK2 that have disrupted the overall integrity of MAPK pathway regulation, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">his retired expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; knockout of the expression MEKK1 or MEKK2 is able to disrupt the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">knockout of the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutation 415G4 may have disrupted potent spike: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">potent spike: (GAR)n-(GAR)n</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; alcohol exposure may have disrupted ocular dominance plasticity.</text>
                    <arg n="0">alcohol exposure</arg>
                    <arg n="1">ocular dominance plasticity</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; if retired from the expression MEKK1 or MEKK2 disrupts the overall integrity of MAPK pathway regulation.</text>
                    <arg n="0">if retired from the expression MEKK1 or MEKK2</arg>
                    <arg n="1">the overall integrity of MAPK pathway regulation</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>When both genes was disrupted, the expression Galish expression is further increased was higher.</text>
                    <arg n="1">both genes</arg>
                    <arg n="2">Galish expression is further increased</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>exposure to alcohol consumption that has disrupted ocular domain plasticity was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">exposure to alcohol consumption</arg>
                    <arg n="1">ocular domain plasticity</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>It is important to point out that R142X disrupt a splicing enhancer.</text>
                    <arg n="0">R142X</arg>
                    <arg n="1">a splicing enhancer</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>It is important to stress that the findings show that Mutation 415G4 disrupt the expression no licensing improvement sequence: (GAR)n-(GAR)n.</text>
                    <arg n="0">Mutation 415G4</arg>
                    <arg n="1">licensing improvement sequence: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>It is important to stress that tumour binding system 2 maneuver is able to disrupt tumour vessels.</text>
                    <arg n="0">tumour binding system 2 maneuver</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Quantitative electrophysiology of a single unit revealed that a homozygotic mutation is able to detach splicing disrupt robust visual responses.</text>
                    <arg n="0">a homozygotic mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Quantitative electrophysiology of a single unit revealed that mutations in this region disrupted assembly of keratin filaments while retaining robust visual responses.</text>
                    <arg n="0">mutations in this region</arg>
                    <arg n="1">assembly of keratin filaments</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Studies using polymerase chain reaction, restriction enzymatic digestion (manipulation of the Tie-2 system in tumors after disrupted tumour vessels, Arg243--His mutation, a Hha I site, and Asp250---Asn mutation, a Taq I site), and allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">manipulation of the Tie-2 system in tumors</arg>
                    <arg n="1">tumour vessels</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (Multations in p53 that can disrupt posts of checkpoints to DNA damage, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">Multations in p53</arg>
                    <arg n="1">posts of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Studies using polymerase chain reaction, restriction enzyme digestion (mutation 415G4 that can disrupt splicing sequencer: (GAR)n-(GAR)n, the Arg243--His mutation, a Hha I site, and the Asp250---Asn mutation, a Taq I site), and the allele-specific oligonucleotide hybridization confirmed that patients were indeed heterozygous compounds for the respective mutations.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>The The mutation 415G4 that disrupted enhancement brush: (GAR)n-(GAR)n was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">The mutation 415G4</arg>
                    <arg n="1">enhancement brush: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>The sequence of the cloned polymerase chain reaction amplified fragments of the AMH gene revealed a deletion of 14-bp in the second exon of the maternal allele; Lys147Ala substitution is able to disrupt interaction.</text>
                    <arg n="0">Lys147Ala substitution</arg>
                    <arg n="1">interaction</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a 14 bp deletion in the second exon of the maternal allele; Mutations in p53 has been shown to disrupt responses of checkpoints to DNA damage.</text>
                    <arg n="0">Mutations in p53</arg>
                    <arg n="1">responses of checkpoints to DNA damage</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>The sequence of the cloned polymerase chain reaction amplifies fragments of the AMH gene revealed a deletion of 14 bp in the second exon of the maternal allele; A mutation 415G4 is able to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>The treatment of systemic inflammatory response to CPB is also confused by the fact that A mutation 415G4 has been shown to disrupt slicing enhancer sequnce: (GAR)n-(GAR)n or to produce immunosuppression.</text>
                    <arg n="0">A mutation 415G4</arg>
                    <arg n="1">slicing enhancer sequnce: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>homozygous mutation that can disrupt splicing that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">homozygous mutation</arg>
                    <arg n="1">splicing</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>mutation 415G4 that can disrupt splicing sequencer: (GAR)n-(GAR)n that has been identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">mutation 415G4</arg>
                    <arg n="1">splicing sequencer: (GAR)n-(GAR)n</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>the Lys147Ala substitution that has disrupted the interaction was identified in affected siblings with classical abetalipoproteinemia.</text>
                    <arg n="0">the Lys147Ala substitution</arg>
                    <arg n="1">the interaction</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
